Keyword: Alnylam Pharmaceuticals
What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
Vir Biotechnology has started trials of its gene-silencing drug for hepatitis B, the first candidate from its partnership with Alnylam Pharmaceuticals.
Intellia Therapeutics is developing a CRISPR-based treatment to edit the mutation that causes transthyretin amyloidosis.
Alnylam says it will have to wait for the final results of a phase 3 trial of acute hepatic porphyria drug givosiran before filing.
Akcea has its first FDA approval for hATTR therapy Tegsedi but will be burdened with a black box warning as it chases rival Alnylam.
The readout linked the ALAS1-targeted RNAi to a drop in urinary ALA, a biomarker Alnylam and the FDA think may predict clinical benefit.
Boehringer’s Corsico jumps to head dev at GSK; Kite’s Polverino takes CSO role at Zymeworks; and Kymera taps former Alnylam executive as CMO.
Jared Gollob, M.D., is joining Kymera Therapeutics, a startup focused on protein degradation.
Pfizer’s ATTR drug tafamidis has hit the mark in a phase 3 trial, setting up regulatory filings and a challenge to rivals Alnylam and Ionis/Akcea.